Sales & Marketing Sponsored Beyond the grid: Rethinking tracking studies for pharma’s ne... As the healthcare landscape continues to evolve rapidly, the tools used to understand it must keep pace.
Partner Content Partner Content Why Does Quant-Led KOL Identification Fail In Growth Markets... When it comes to KOL identification mapping, there is no shortage of quant data around KOL and HCP activity out there.
Partner Content Partner Content Mapping Human Influence Uncovering drivers of influence with qual inputs
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.